Al Jazeera English image for Why Guinea-Bissau halted a controversial hepatitis vaccine trial for babies - Al Jazeera

❤️ Health · Al Jazeera English

Why Guinea-Bissau halted a controversial hepatitis vaccine trial for babies - Al Jazeera

From Al Jazeera English via USVI News: Experts have said the US-funded trial would deny critical vaccines to thousands of infants.

USVInews.com User Network Contributor

Guinea-Bissau has reportedly halted a controversial United States-funded hepatitis B virus vaccine (HBV) trial which drew global scrutiny when experts said it involved withholding lifesaving shots from thousands of babies.

The trial failed to gain the necessary government approval, one researcher involved in the project said in a statement, adding that the end of the trial was a “significant setback” for African science.

- list 1 of 4 Port Sudan families can barely afford water as shortages persist

- list 2 of 4 Israel restricting treatment for 1,100 child amputees in Gaza: NGO

- list 3 of 4 Dakar Youth Olympics: Who gets to hold the flame?

- list 4 of 4 Education under fire: Gaza’s children face death on their way to school

Officials have not commented.

The West African nation’s judicial police said in mid-October that it had raided the facilities of the research group leading the project in the capital, Bissau, and seized vaccine batches.

Authorities said inquiries were continuing to determine whether the trial had complied with the country’s safety standards.

What was the trial about?

The trial was designed to assess the effects of World Health Organization (WHO)-recommended HBV vaccines on two groups of babies. One group would receive the vaccine at birth, and another, chosen at random, would receive it six weeks later.

Some 14,000 babies were expected to be involved in the trial. The researchers planned to assess health outcomes over five years for the two sets.

The project secured $1.6m from the US Centers for Disease Control and Prevention (CDC) under Health Secretary Robert F Kennedy, who has previously made his anti-vaccine views known.

However, the announcement of the trial in December last year met with widespread anger over the withholding of the vaccine from one set of babies. In January, the Guinea-Bissau government paused the project and launched a review.

Who was leading the trial?

The Danish research group, Bissau-based Bandim Health Project, part of the University of Southern Denmark, planned the trial.

It is chaired by prominent scientists Christine Stabell Benn and Peter Aaby, a married couple. Since 1978, they have run the Bandim Health Project out of Bissau and have conducted studies on thousands of Bissau-Guineans.

Both researchers primarily study unintended impacts of vaccines and have theorised that vaccines which contain inactivated viruses can cause death, including the HBV vaccine which they planned to test in Bissau.

Their counterparts in Denmark have, however, repeatedly accused them of downplaying trial results or withholding evidence that does not align with their narrative.

One of the pair’s studies found that WHO-approved vaccines against diphtheria, tetanus and pertussis (DTP) led to higher infant deaths, especially for girls. WHO said the pair’s study was inconsistent but merited further review, and advised countries to keep vaccinating babies.

Last February, investigations by the Danish publication, Weekendavisen, found that the researchers had not publicised the null results of one of their randomised controlled trials (RCTs) on the DTP vaccine conducted 14 years ago. The study was published after the expose.

Why is the hepatitis B trial controversial?

In this case, health experts questioned the morality of withholding a highly effective vaccine from thousands of babies for the purposes of research. WHO called it “unethical”.

Infants are at the highest risk of being chronically infected with hepatitis B – usually passed to them from their mothers. The disease has no cure and can lead to long-term liver damage and cancer. WHO recommends HBV vaccines at birth for all babies, as well as booster shots, which are known to offer years of protection.

Guinea-Bissau has one of the highest numbers of people living with hepatitis B – one-fifth of the 2.2 million population. Because it cannot access enough doses, the government authorises the vaccine at up to six weeks after birth. However, it is working to start at-birth hepatitis B vaccination for all babies from 2028.

The researchers argued that the timeframe between now and 2028 provides a “unique window of opportunity” to assess how the vaccine affects babies who receive it at birth against those who receive it after six weeks. They noted that the research would see thousands of babies receive the shot at birth before the official schedule kicks in.

This article is republished through the USVI News affiliate desk. Reporting, analysis, and viewpoints are those of the original publisher and do not necessarily reflect USVI News.

Read more at Al Jazeera English